Mentions:
1: Andrew Western (Lab - Stretford and Urmston) Macmillan Cancer Support estimates that a cancer diagnosis leads to a person being around £570 a month - Speech Link
2: Richard Foord (LD - Tiverton and Honiton) Oral cancer is one of the fastest-growing types of cancer and it is killing more people than car accidents - Speech Link
3: Paulette Hamilton (Lab - Birmingham, Erdington) Some 80% of people with pancreatic cancer are diagnosed at stages 3 and 4.People with cancer need fast - Speech Link
4: Kirsty Blackman (SNP - Aberdeen North) The negative change there is causing a problem.Specifically on cancer patients and the cancer strategy - Speech Link
5: Preet Kaur Gill (LAB - Birmingham, Edgbaston) As we heard today, according to research by Macmillan Cancer Support, four in five cancer patients are - Speech Link
Apr. 12 2024
Source Page: Non-technical summaries granted in 2024Found: pancreatic cancer.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will encourage the National Institute for Health and Care Research to rigorously evaluate existing research efforts and review how they can further prioritise and drive research investment for pancreatic cancer and other less survivable cancers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.
In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will establish targeted funding to prioritise and drive research investment into pancreatic cancer and the other less survivable cancers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.
In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Paulette Hamilton (Labour - Birmingham, Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that all people diagnosed with pancreatic cancer who are eligible for clinical trials are able to access those trials.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government has set out a vision for the Future of UK Clinical Research Delivery, which aims to create a patient-centred, pro-innovation, and digitally enabled clinical research environment. Key to achieving this vision is increasing participation in research to ensure that the research we support is inclusive and representative of the populations we serve.
The Department-funded National Institute for Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research. For example, in financial year 2022/23, the NIHR Clinical Research Network supported 41 pancreatic cancer studies and recruited 1,004 participants to these studies.
In addition, the NIHR provides an online service called Be Part of Research which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This makes it easier for people to find and take part in health and care research that is relevant to them.
When designing research studies, researchers consider inclusion and exclusion criteria carefully to ensure they are not unnecessarily excluding specific groups who would benefit from the outcome of their study. However, we are aware that inclusion and exclusion criteria can disproportionally exclude individuals from specific groups, for example older adults or pregnant women.
The Health Research Authority (HRA) is developing guidance to improve practices in this area. We are not aware that people with pancreatic cancer are routinely being excluded from studies, however, we know that sometimes people are automatically excluded from taking part, and this can be for good reasons. The guidance produced by the HRA will help researchers to consider if these people and any other groups of people may be unnecessarily excluded, and consider putting measures in place to address this.
Asked by: Paulette Hamilton (Labour - Birmingham, Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on the impact of staffing on the (a) National Cancer Patient Experience Survey programme and (b) collection of data on people with pancreatic cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are not aware of an impact of staffing on the National Cancer Patient Experience Survey programme, or on the collection of data on people with pancreatic cancer.
The Department is working closely with NHS England to make sure we have the right workforce with the right skills, across the country. In 2023, the National Health Service published the first ever Long Term Workforce Plan, backed by over £2.4 billion of Government funding, to deliver the biggest training expansion in NHS history. Regarding cancer specifically, the number of staff in the cancer workforce has increased by 50% since 2010.
The 2022 National Cancer Patient Experience survey showed respondents’ average rating of care was 8.8 out of 10, with zero being very poor and 10 very good. 75.5% of respondents said they definitely received the right amount of support for their overall health and wellbeing from hospital staff.
Mar. 19 2024
Source Page: Meetings with Scottish Fire and Rescue Service and Fire Brigades Union: FOI releaseFound: QUERY (EXPRESS) Pancreatic Cancer UK release below which features a Fife supporting their “Don’t Write
Correspondence Mar. 18 2024
Committee: Health, Social Care and Sport CommitteeFound: Hollywood, VP Hepatology, British Society Gastroenterology Dr Sorcha Hume, Public Affairs Manager, Cancer
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 29 May 2023Found: the skin cancer.
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 27 March 2023Found: There is no preclinical or clinical signal for pancreatitis or pancreatic cancer. 05JT2ZMK-0431A